Highlights

  • The a2 Milk Company (ASX:A2M) reported that estimated China-label formula offtake had recovered to approximately 50% of pre-disruption levels.
  • The November update expects FY27 Revenue and EBITDA growth, although group Earnings are expected to be weighted toward the second half.
  • FY26 continuing-operations revenue increased 12.4% to NZD 1,974.9 million, while reported EBITDA declined 2.5% to NZD 284.4 million.
  • The company now expects around NZD 15 million in FY27 one-off transformation costs associated with its Pokeno integration and product transition.

The a2 Milk Company Limited (ASX:A2M) markets branded dairy nutrition products, including infant formula and liquid milk, across international markets. Its shares were quoted at AUD 6.47 on 20 November 2026, with no session percentage change confirmed in the supplied figures. A November trading update has shifted attention toward China formula availability, product launches and the FY27 earnings profile.

China Formula Recovery Remains Central to FY27

At its November annual meeting, the company said estimated China-label infant milk formula offtake had improved to approximately 50% of levels before its Supply disruption, compared with about 40% in August. The disruption had constrained product availability in the fourth quarter of FY26, and management said some established customers switched to competing products when supply was limited. This makes the recovery of availability and consumer purchasing behaviour central to the current financial year.

The group expects total infant formula sales in FY27 to be broadly similar to FY26, with China-label and English-label products rebuilding progressively. Its update identified recently launched China-label products and a refreshed a2 Platinum range as part of that plan.

FY26 Revenue Growth and Earnings Comparisons

For the year ended 30 June 2026, continuing-operations revenue reached NZD 1,974.9 million, an increase of 12.4% from NZD 1,757.2 million. Reported EBITDA was NZD 284.4 million, compared with NZD 291.7 million, while underlying EBITDA rose 5.4% to NZD 307.6 million. The different EBITDA movements matter because the underlying measure excludes specified Pokeno losses and transformation costs. Reported net profit after tax from continuing operations was NZD 207.5 million, down 5.8%.

The company also reported underlying net profit after tax of NZD 235.8 million, up 7.0% on the comparable period. The China supply interruption affected the later part of FY26, while growth in other product categories contributed to revenue.

Pokeno Transition and the Second-Half Outlook

The company expects both revenue and EBITDA to grow in FY27, supported by new products and markets, Other Nutritionals, Liquid Milk and improved profitability at a2 Pokeno. It also expects revenue and EBITDA to be materially weighted toward the second half, reflecting the timing of formula recovery and higher Marketing activity in the first half.

The transition of a2 Platinum production to Pokeno was described as on track in the November update. One-off FY27 transformation costs are now expected to total approximately NZD 15 million, including about NZD 5 million of Pokeno integration expenses and NZD 10 million relating to product transition. The company does not expect further transformation costs in FY28.

Operating Risks and Sector Considerations

China infant formula regulation, Import requirements and product availability remain important commercial considerations for the business. The latest update demonstrates that restoring supply does not immediately restore Demand when some buyers have changed brands. Marketing expenditure and product relaunches may therefore affect the timing and cost of a recovery. Foreign-exchange movements create an additional distinction between reported sales translation and eventual earnings.

What to Watch Next

The next measurable developments are the pace of China-label offtake recovery, the availability of a2 Genesis and the performance of newly launched products. Investors may also monitor whether the Pokeno production transition remains aligned with management’s plan. First-half FY27 earnings will offer evidence about marketing costs and the expected second-half weighting. Subsequent updates should clarify whether the existing FY27 outlook remains appropriate.

Key Insights

The latest annual-meeting update places formula supply and customer recovery alongside Pokeno execution at the centre of FY27 monitoring. FY26 revenue increased, but reported and underlying earnings moved differently. The timing of product availability, transition expenditure and second-half sales will determine how management’s outlook is tested.